相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia
A. Burchert et al.
LEUKEMIA (2015)
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2015)
Regulation of antiviral T cell responses by type I interferons
Josh Crouse et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Elias Jabbour et al.
BLOOD (2014)
Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms
Dennis Niebel et al.
BLOOD (2014)
How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia
David M. Ross et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
Ruediger Hehlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Immunology and Immunotherapy of Chronic Myeloid Leukemia
Mette Ilander et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2014)
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Susan Branford et al.
BLOOD (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
M. Talpaz et al.
LEUKEMIA (2013)
Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go
Angela Vasaturo et al.
FRONTIERS IN IMMUNOLOGY (2013)
Depletion of Plasmacytoid Dendritic Cells Inhibits Tumor Growth and Prevents Bone Metastasis of Breast Cancer Cells
Anandi Sawant et al.
JOURNAL OF IMMUNOLOGY (2012)
Standardized definitions of molecular response in chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2012)
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
R. A. Larson et al.
LEUKEMIA (2012)
Pushing the limits of targeted therapy in chronic myeloid leukaemia
Thomas O'Hare et al.
NATURE REVIEWS CANCER (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system?
Boris Reizis et al.
NATURE REVIEWS IMMUNOLOGY (2011)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
Andreas Burchert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Harmonization of molecular monitoring of CML therapy in Europe
M. C. Mueller et al.
LEUKEMIA (2009)
Antigen-presentation properties of plasmacytoid dendritic cells
Jose A. Villadangos et al.
IMMUNITY (2008)
Plasmacytoid dendritic cells mediate oral tolerance
Anne Goubier et al.
IMMUNITY (2008)
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Philippe Rousselot et al.
BLOOD (2007)
Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts
Jordi C. Ochando et al.
NATURE IMMUNOLOGY (2006)
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
LP Chen
NATURE REVIEWS IMMUNOLOGY (2004)
To the editor: Discontinuation of imatinib therapy after achieving a molecular response
J Cortes et al.
BLOOD (2004)
Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells
EA Moseman et al.
JOURNAL OF IMMUNOLOGY (2004)
Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission
MJ Mauro et al.
LEUKEMIA RESEARCH (2004)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
H Ueda et al.
NATURE (2003)
Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-speciflic T cells
JJ Molldrem et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Complete cytogenetic and molecular responses to interferon-α-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis
HM Kantarjian et al.
CANCER (2003)
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia
A Burchert et al.
BLOOD (2003)
Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells
M Gilliet et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
Mouse type IIFN-producing cells are immature APCs with plasmacytoid morphology
C Asselin-Paturel et al.
NATURE IMMUNOLOGY (2001)
Chronic myeloid leukemia and interferon-α:: a study of complete cytogenetic responders
F Bonifazi et al.
BLOOD (2001)
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes
B Salomon et al.
IMMUNITY (2000)
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
JJ Molldrem et al.
NATURE MEDICINE (2000)
分享论文
